Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27997963 | 0.81 | GRIN2B (0.40) | GRIN2BKCNQ3KCNQ2 | |
| SCHEMBL1409516 | 0.78 | FEN1 (0.54) | PIK3CD | |
| SCHEMBL8015322 | 0.76 | NR4A2 (0.40) | CYP2A6NPC1RAB9A | |
| SCHEMBL1744099 | 0.76 | CYP2A6 (0.47) | PIK3CDCYP2A6NPC1RAB9A | |
| SCHEMBL30213578 | 0.73 | GABRG2 (0.45) | GRIN2B | |
| SCHEMBL1662273 | 0.72 | PIK3CD (0.73) | PIK3CDCYP2A6NOTUMNPC1RAB9A | |
| SCHEMBL8612501 | 0.72 | FEN1 (0.42) | NPC1RAB9A | |
| SCHEMBL10899210 | 0.72 | AHR (0.52) | PIK3CDCYP2A6NPC1RAB9A | |
| SCHEMBL21613507 | 0.71 | GRIN2B (0.43) | GRIN2B | |
| SCHEMBL1513625 | 0.70 | ESR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101805298-A | Novel aryl-with heteroaryl-piperazine | HIGH POINT PHARMACEUTICALS LLC | 2010-08-18 | — | — | CN | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| CN-1628109-A | Novel aryl-and heteroaryl-piperazines | NOVO NORDISK AS (DK) | 2005-06-15 | — | — | CN | disclosed |
| EP-1474401-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| WO-2003066604-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | PIK3CD 1742/4885CYP2A6 888/4885GRIN2B 243/4885 |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HRH3, HRH2, HRH4 | PIK3CD 1742/4885CYP2A6 888/4885GRIN2B 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.